retatrutide and dopamine Retatrutide—A Game Changer in Obesity Pharmacotherapy GLP-1 Medications and the Brain

Prescribing without evidence: pregnancy

They found that intestinal flora may mediate the release of the intestinal hormone GLP-1 through the short-chain fatty acid (SCFA)-GPCR pathway, thereby increasing satiety and slowing gastric emptying, ultimately reducing obesity

In fact, just seven out of the 29 studies investigated the consummatory phase of reward (Bogdanov et al., 2020

It is long enough to get under the skin but not so long that it penetrates muscle

6 Because GLP-1 medicines facilitate improvements in both the metabolic system (e.g., appetite hormones) and brain reward centers, this likely accounts for why they are uniquely effective at reducing food noise symptoms